Toxoplasma gondii: The immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis

Experimental Parasitology

Volumn 123, Issue 1, 2009, Pages 81-89

  Dziadek, Bozena ^a   Gatkowska, Justyna ^a   Brzostek, Anna ^b   Dziadek, Jaroslaw ^b   Dzitko, Katarzyna ^a   Dlugonska, Henryka ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

Immunoprotection; Recombinant ROP2; Recombinant ROP4; Subunit vaccines; Toxoplasma gondii

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; INTERLEUKIN 2; RECOMBINANT ROP2 ANTIGEN; RECOMBINANT ROP4 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BRAIN CYST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOGENICITY; MALE; MOLECULAR CLONING; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; TH2 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ANTIBODIES, PROTOZOAN; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RABBITS; RECOMBINANT PROTEINS; SPLEEN; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, SUBUNIT;

ANIMALIA; ESCHERICHIA COLI; MURINAE; MUS; TOXOPLASMA; TOXOPLASMA GONDII;

EID: 67949107942     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2009.06.002     Document Type: Article

References (48)

1. Black M.W., and Boothroyd J.C. Lytic cycle of Toxoplasma gondii. Microbiology and Molecular Biology Reviews 64 (2000) 607-623
2. Boothroyd J.C., and Dubremetz J.F. Kiss and spit: the dual roles of Toxoplasma rhoptries. Nature Reviews Microbiology 6 (2008) 79-88
3. Buxton D., and Innes E.A. A commercial vaccine for ovine toxoplasmosis. Parasitology 110 (1995) 11-16
4. Chardes T., Bourguin I., Mevelec M.N., Dubremetz J.F., and Bout D. Antibody responses to Toxoplasma gondii in sera, intestinal secretions, and milk from orally infected mice and characterization of target antigens. Infection and Immunity 58 (1990) 1240-1246
5. Denkers E.Y. T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii. Microbes and Infection 1 (1999) 699-708
6. Denkers E.Y., and Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clinical Microbiology Reviews 11 (1998) 569-588
7. Doskaya M., Kalantari-Dehaghi M., Walsh C.M., Hiszczynska-Sawicka E., Davies D.H., Fengler P.L., Larsen L.S.Z., Lathrop R.H., Hatfield G.W., Schulz J.R., Guruz Y., and Jurnak F. GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine. Vaccine 25 (2007) 1824-1837
8. Dubey J.P. Status of toxoplasmosis in sheep and goats in the United States. Journal of the American Veterinary Medical Association 196 (1990) 259-262
9. Dubremetz J.F. Rhoptries are major players in Toxoplasma gondii invasion and host cell interaction. Cellular Microbiology 9 (2007) 841-848
10. Dziadek B., Dziadek J., and Dlugonska H. Identification of Toxoplasma gondii proteins binding human lactoferrin: a new aspect of rhoptry proteins function. Experimental Parasitology 115 (2007) 277-282
11. Echeverria P.C., De Miguel N., Costas M., and Angel S.O. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine 24 (2006) 4102-4110
12. El Hajj H., Demey E., Poncet J., Lebrun M., Wu B., Galeotti N., Fourmaux M.N., Mercereau-Puijalon O., Vial H., Labesse G., and Dubremetz J.F. The ROP2 family of Toxoplasma gondii rhoptry proteins: proteomic and genomic characterization and molecular modeling. Proteomics 6 (2006) 5773-5784
13. Fachado A., Rodriguez A., Angel S.O., Pinto D.C., Vila I., Acosta A., Amendoeira R.R., and Lannes-Vieira J. Protective effect of naked DNA vaccine cocktail against lethal toxoplasmosis in mice. Vaccine 21 (2003) 1327-1335
14. Gatkowska J., Gasior A., Kur J., and Dlugonska H. Toxoplasma gondii: Chimeric Dr fimbriae as a recombinant vaccine against toxoplasmosis. Experimental Parasitology 118 (2008) 266-270
15. Golkar M., Shokrgozar M.A., Rafati S., Musset K., Assmar M., Sadaie R., Cesbron-Delauw M.F., and Mercier C. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 25 (2007) 4301-4311
16. Hill D., and Dubey J.P. Toxoplasma gondii: transmission, diagnosis and prevention. Clinical Microbiology and Infection 8 (2002) 634-640
17. Igarashi M., Kano F., Tamekuni K., Machado R.Z., Nawarro I.T., Vidotto O., Vidotto M.C., and Garcia J.L. Toxoplasma gondii: evaluation of an intranasal vaccine using recombinant proteins against brain cyst formation in BALB/c mice. Experimental Parasitology 118 (2008) 386-392
18. Innes E.A., and Vermeulen A.N. Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora. Parasitology 133 (2006) 145-168
19. Jongert E., Verhelst D., Abady M., Petersen E., and Gargano N. Protective Th1 immune responses against chronic toxoplasmosis induced by a protein-protein vaccine combination but not by its DNA-protein counterpart. Vaccine 26 (2008) 5289-5295
20. Kang H., Remington J.S., and Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-γ, TNF-α, and inducible nitric oxide synthase. The Journal of Immunology 164 (2000) 2629-2634
21. Kijlstra A., and Jongert E. Control of the risk of human toxoplasmosis transmitted by meat. International Journal for Parasitology 38 (2008) 1359-1370
22. Letscher-Bru V., Villard O., Risse B., Zauke M., Klein J.P., and Kien T. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice. Infection and Immunity 66 (1998) 4503-4506
23. Letscher-Bru V., Pfaff A.W., Abou-Bacar A., Filisetti D., Antoni E., Villard O., Klein J.P., and Candolfi E. Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice. Infection and Immunity 71 (2003) 6615-6619
24. Leyva R., Herion P., and Saavedra R. Genetic immunization with plasmid DNA coding the ROP2 protein of Toxoplasma gondii. Parasitology Research 87 (2001) 70-79
25. Lourenco E.V., Bernardes E.S., Silva N.M., Mineo J.R., Panunto-Castelo A., and Roque-Barreira M.C. Immunization with MIC1 and MIC4 induces protective immunity against Toxoplasma gondii. Microbes and Infection 8 (2006) 1244-1251
26. Martin V., Arcavi M., Santillan G., Amendoeira M.R.R., De Souza Neves E., Griemberg G., Guarnera E., Garberi J.C., and Angel S.O. Detection of human Toxoplasma-specific immunoglobulins A, M, and G with a recombinant Toxoplasma gondii Rop2 protein. Clinical and Diagnostic Laboratory Immunology 5 (1998) 627-631
27. Martin V., Supanitsky A., Echeverria P.C., Litwin S., Tanos T., De Roodt A.R., Guarnera E.A., and Angel S.O. Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis. Clinical and Diagnostic Laboratory Immunology 11 (2004) 704-710
28. Mevelec M.N., Mercereau-Puijalon O., Buzoni-Gatel D., Bourguin J., Chardes T., Dubremetz J.F., and Bout D. Mapping of B epitopes in GRA4, a dense granule antigen of Toxoplasma gondii and protection studies using recombinant proteins administered by the oral route. Parasite Immunology 20 (1998) 183-195
29. Miller C.M., Boulter N.R., Ikin R.J., and Smith N.C. The immunobiology of the innate response to Toxoplasma gondii. International Journal for Parasitology 39 (2009) 23-39
30. Mishima M., Xuan X., Shioda A., Omata Y., Fujisaki K., Nagasawa H., and Mikami T. Modified protection against Toxoplasma gondii lethal infection and brain cyst formation by vaccination with SAG2 and SRS1. Parasitology 63 (2001) 433-438
31. Nakaar V., Ngo H.M., Aaronson E.P., Coppens I., Stedman T.T., and Joiner K.A. Pleiotropic effect due to targeted depletion of secretory rhoptry protein ROP2 in Toxoplasma gondii. Journal of Cell Science 116 (2003) 2311-2320
32. Petersen E., Nielsen H.V., Christiansen L., and Spenter J. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine 16 (1998) 1283-1289
33. Pfaff A.W., and Candolfi E. New insights in toxoplasmosis immunology during pregnancy. Perspective for vaccine prevention. Parasitologia 50 (2008) 55-58
34. Saavedra R., De Meuter F., Decourt J.L., and Herion P. Human T cell clone identifies a potentially protective 54-kDa protein antigen of Toxoplasma gondii cloned and expressed in Escherichia coli. The Journal of Immunology 147 (1991) 1975-1982
35. Saavedra R., Becerril M.A., Dubeaux C., Lippens R., De Vos M.J., Herion P., and Bollen A. Epitopes recognized by human T lymphocytes in the ROP2 protein antigen of Toxoplasma gondii. Infection and Immunity 64 (1996) 3858-3862
36. Sadak A., Taghy Z., Fortier B., and Dubremetz J.F. Characterization of a family of rhoptry proteins of Toxoplasma gondii. Molecular and Biochemical Parasitology 29 (1988) 203-211
37. Sambrook J., and Russell D.W. Molecular Cloning: A Laboratory Manual. third ed. (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
38. Sayles P.C., Gibson G.W., and Johnson L.L. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infection and Immunity 68 (2000) 1026-1033
39. Schaap D., Vermeulen A.N., Roberts C.W., and Alexander J. Vaccination against toxoplasmosis: current status and future prospects. In: Weiss L.M., and Kim K. (Eds). Toxoplasma gondii. The model Apicomplexan. Perspectives and methods (2007), Academic Press, San Diego 721-759
40. Sheffield P., Garrard S., and Derewenda Z. Overcoming expression and purification problems of RhoGDI using a family of "parallel" expression vectors. Protein Expression and Purification 15 (1999) 34-39
41. Siachoque H., Guzman F., Burgos J., Patarroyo M.E., and Marin J.E.G. Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model. Experimental Parasitology 114 (2006) 62-65
42. Sinai A.P., and Joiner K.A. The Toxoplasma gondii protein ROP2 mediates host organelle association with the parasitophorous vacuole membrane. The Journal of Cell Biology 154 (2001) 95-108
43. Van Gelder P., Bosman F., De Meuter F., Van Heuverswyn H., and Herion P. Serodiagnosis of toxoplasmosis by using a recombinant form of the 54-kilodalton rhoptry antigen expressed in Escherichia coli. Journal of Clinical Microbiology 31 (1993) 9-15
44. Vercammen M., Scorza T., Huygen K., De Braekeleer J., Diet R., Jacobs D., Saman E., and Verschueren H. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infection and Immunity 68 (2000) 38-45
45. Xue M., He S., Cui Y., Yao Y., and Wang H. Evaluation of the immune response elicited by multi-antigenic DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii. Parasitology International 57 (2008) 424-429
46. Xue M., He S., Zhang J., Cui Y., Yao Y., and Wang H. Comparison of cholera toxin A2/B and murine interleukin-12 as adjuvants of Toxoplasma multi-antigenic SAG1-ROP2 DNA vaccine. Experimental Parasitology 119 (2008) 352-357
47. Yang C.D., Chang G.N., and Chao D. Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2. Parasitology Research 92 (2004) 58-64
48. Zhang J., He S., Jiang H., Yang T., Cong H., Zhou H., Zhang J., Gu Q., Li Y., and Zhao Q. Evaluation of the immune response induced by multiantigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice. Parasitology Research 101 (2007) 331-338